Mami Hino has experience in representing the world’s leading technology companies for many years in disputes, litigation and transactions. Mami’s practice emphasizes invalidity trials and resultant IP High Court appeals, cross-border infringement litigation, strategic patent prosecution, client counseling, and opinions. She collaborates with a variety of clients from heavy machinery companies to consumer product companies, including chemical companies and pharmaceutical companies.
Due to her background as a registered pharmacist, Mami has extensive experience representing innovator pharmaceutical companies to protect their patents, such as filing patent term extension applications, defending their patents in invalidity trials and IP High Court appeals, filing preliminary injunction requests and/or patent infringement suits against generic drug companies.
Mami studied law at a U.S. law school (J.D.) and practiced as an attorney at a New York law firm that specializes in intellectual property. She can provide foreign clients with Japanese IP advice by utilizing her understanding of the differences between foreign IP practice and Japanese IP practice.
- Japan, Intellectual Property: Domestic (Band 1) for 11 consecutive years – Chambers Global (2012-2022)
- Japan, Intellectual Property: Domestic (Band 1) for 11 consecutive years – Chambers Asia-Pacific (2012-2022)
- Patent Star, Japan for 10 consecutive years – IP Stars, Managing Intellectual Property (2014-2023)
- The World’s Leading Patent Professionals, Japan: Domestic for 12 consecutive years – IAM Patent 1000 (2012-2023)
- One of the leading patent attorneys in Japan for 9 consecutive years – Who’s Who Legal (2014-2022)
- Influential Women in IP – World Intellectual Property Review (2019-2020)
- The Top 250 Women in IP for 2 consecutive years – IP Stars, Managing Intellectual Property (2021-2022)
- Asia-Pacific’s Top 100 Women in Litigation – Benchmark Litigation for 3 consecutive years (2020-2022)
- Top Female Legal Practitioner in Life Sciences – Women in Business Law Expert Guide (2021)
- WIPR Leader – for 2 consecutive years (2022-2023)
Seton Hall University School of Law, USA 1999, J.D.
Kyoto University, Japan 1984, Bachelor of Pharmacy
New York
Patent Attorney (admitted to practice intellectual property infringement litigation) in Japan
Foreign legal consultant in Japan
Pharmacist in Japan
Abe Ikubo & Katayama (Counsel, 2004-2006; Partner, 2006-Present)
Baker & McKenzie, Tokyo (Associate, 2002-2004)
Pennie & Edmonds (Law Clerk, 1998-2000; Associate, 2000-2002)
Asahina Co., (Technical Advisor, 1990-1994; Associate, 1994-1996)
Fujisawa Pharmaceutical Company (Research Pharmacist 1984-1987)
Member of Intellectual Property Experts Committee at Japan Agency for Medical Research and Development (2015-Present)
Member of Intellectual Property Utilization Support Project Review Committee at Japan Science and Technology Agency (2010-2014)
- AIPPI Japan
- Intellectual Property Owners Association
- Tokyo IP American Inn of Court
“Amgen v. Sanofi and Regeneron: Japan IP High Court overrules its own decision on validity of Amgen patent” (Kluwer Patent Blog 2023) co-author
“Japan IP High Court’s first-ever decision allowing patent enforcement against infringing acts partially committed outside of Japan” (Kluwer Patent Blog 2022) co-author
“Japan: Guidelines for a Transparent and Predictable SEP Licensing Negotiation” (Kluwer Patent Blog 2022) co-author
“Japan: Problem of Japan’s patent linkage system comes to the surface by a set of IP High Court decisions” (Kluwer Patent Blog 2022) co-author
“Japan: PD-1/PD-L1 related patents: What are the co-inventorship requirements for an invention in the medicine field” (Kluwer Patent Blog 2022) co-author
“Amicus Curiae Practice is Set to Make Its Statutory Debut in Japan” (IP Watchdog 2022) co-author
“Japan: MSD v Wyeth – The IP High Court upholds the validity of patent claims, finding inventive step in the functional limitation therein” (Kluwer Patent Blog 2021) co-author
“A Japanese version Amicus Brief system will be introduced in spring 2022” (Kluwer Patent Blog 2021) co-author
“Japan: The IP High Court has clarified that the Japanese Bolar exemption covers clinical testing for not only “generic” but also “innovator” drugs” (Kluwer Patent Blog 2021) co-author
“Patent Term Extension in Japan －Recent IP High Court Grand Panel Decision－” (A.I.P.P.I. September 2014)
“Intellectual Property in Electronics and Software” (Globe Business Publishing 2013)
“Intellectual Property in the Life Sciences” (Globe Business Publishing 2011)
“Japanese Patent Litigation” 2nd Ed. (WEST 2010)